Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Ranbaxy Issues Voluntary Nationwide Recall Of 41 Lots Of Atorvastatin Calcium Tablets 10 Mg, 20 Mg And 40 Mg Due To Potential Pr

Posted Nov 28 2012 3:20pm
ATORVASTATIN Calcium Tablets 10mg x 90243614490's Bottle63304-827-9031-Aug-14ATORVASTATIN Calcium Tablets 10mg x 90243658290's Bottle63304-827-9031-Aug-14ATORVASTATIN Calcium Tablets 10mg x 90244156790's Bottle63304-827-9031-Aug-14ATORVASTATIN Calcium Tablets 10mg x 90244156890's Bottle63304-827-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243673190's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243738190's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243794090's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243794290's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243794590's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243794790's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243795290's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243795390's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90243796090's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90244067690's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90244067790's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90244068090's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 20mg x 90244068190's Bottle63304-828-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 5002437956500's Bottle63304-829-0531-Aug-14ATORVASTATIN Calcium Tablets 40mg x 5002437957500's Bottle63304-829-0531-Aug-14ATORVASTATIN Calcium Tablets 40mg x 5002440675500's Bottle63304-829-0531-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243426590's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243426690's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243482490's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243482690's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243482790's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243482890's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243482990's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243483090's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243483190's Bottle63304-829-9031-Jul-14ATORVASTATIN Calcium Tablets 40mg x 90243658090's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243672590's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243672790's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243672990's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243737790's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243738090's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243794190's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243794390's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243794490's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243794990's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243795090's Bottle63304-829-9031-Aug-14ATORVASTATIN Calcium Tablets 40mg x 90243795590's Bottle63304-829-9031-Aug-14
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

Contact:
Consumer:
1-866-266-7623

Media:
Charles Caprariello
609-720-5615
 

FOR IMMEDIATE RELEASE - November 28, 2012 - Princeton, NJ -- On November 9, 2012, Ranbaxy Inc. initiated a voluntary  recall  of 41 affected lots of Atorvastatin Calcium Tablets (10 mg, 20 mg and 40 mg) which is a solid oral dosage form, to the retail level. The Company is taking this voluntary action as a precautionary measure due to the fact that we cannot exclude the possibility that the affected lots may contain very small glass particles resembling a fine grain of sand (less than 1 mm in size). This information is available in Ranbaxy’s website at www.ranbaxyusa.com . The recall does not affect or relate to the 80 mg dosage strength of Atorvastatin Calcium Tablets.

The probability of an adverse event due to consumption of this product is unlikely but cannot be ruled out. Because of the size of the particles which may be present in the affected lots it is unlikely to cause a significant safety concern. However, the possibility of adverse experiences arising primarily due to physical irritation cannot be ruled out. As of this date, Ranbaxy has not received any reports of adverse events related to this recall.

The product is used to lower blood cholesterol and is packaged in plastic bottles, as 90 and 500 tablets per bottle. The affected lots of Atorvastatin Calcium Tablets and their respective NDC code, expiration date information are listed below. The product is a white colored tablet and can be identified by the imprint RX12 on 10 mg tablets, RX828 on 20 mg tablets and RX829 on 40 mg tablets. The product was distributed in the USA to wholesalers and retailers.

Ranbaxy has notified its distributors and retailers by e-mail/ FedEx and has arranged for return of the affected lots. Distributors/retailers have stopped further distribution of the affected lots and are in the process of returning any affected product to Ranbaxy.

Consumers with questions regarding this recall can contact Ranbaxy’s Customer Coordinator (Inmar) at 1-866-266-7623, Monday to Friday, 8:00 AM to 5:00 PM CST. Consumers should immediately contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm . Mail to address on the pre-addressed form.
  • Fax: 1-800-FDA-0178
  • This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

    Following is the list of affected lots:

    ProductLot numberPack SizeNDC #Expiry Date
     
     
     
    About Ranbaxy Inc.

    Ranbaxy Inc. is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company.

        
    Post a comment
    Write a comment:

    Related Searches